REPORT HIGHLIGHT
The Cancer Immunotherapy Market size was valued at USD 87,908.6 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.
Cancer immunotherapy is a sort of cancer treatment that uses the body's own immune system to combat cancer. It works by assisting the immune system in recognizing and attacking cancer cells. Immunotherapy can be used alone or in conjunction with other cancer treatments. Cancer frequently overcomes many of the immune system's natural defenses, allowing cancer cells to proliferate. Different types of immunotherapy work in different ways. Some immunotherapy treatments assist the immune system block or limiting the growth of cancer cells. Others aid the immune system in destroying cancer cells or preventing cancer from spreading to other parts of the body. Immunotherapy has shown promise in treating a variety of cancers and has become a major focus of cancer research.
Cancer Immunotherapy Market- Market Dynamics:
- The growing incidence of cancer and the surge in technological advancements in cancer treatment therapies are expected to propel the growth of the global cancer immunotherapy market.
- The expanding cancer burden has produced a critical demand for more effective and tailored treatment alternatives. Cancer immunotherapy has demonstrated encouraging outcomes in treating several types of cancer and is gradually being regarded as an important component of modern cancer treatment techniques. According to the Centers for disease control and Prevention, In the United States in 2020, 1,603,844 new cancer cases were reported and 602,347 people died of cancer. For every 100,000 people, 403 new cancer cases were reported and 144 people died of cancer. 2020 is the latest year for which incidence data are available. Rapid technological advances in cancer research have resulted in the creation of novel and tailored medicines. Immunotherapy, in particular, has made considerable advances in recognition of the advent of immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, oncolytic viruses, and other innovative techniques. As healthcare infrastructure in emerging nations accelerates, there will be greater opportunities for cancer immunotherapies to be adopted. However, High expenses can prevent many patients from gaining Cancer Immunotherapy, particularly in less rich nations or regions.
Cancer Immunotherapy Market- Key Insights:
- As per the analysis shared by our research analyst, the global Cancer Immunotherapy market is estimated to grow annually at a CAGR of around 13.8% over the forecast period (2023-2030)
- The Cancer Immunotherapy industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
- Based on product type segmentation, Monoclonal Antibodies were predicted to show maximum market share in the year 2022
- Based on Application segmentation, Lung Cancer was the leading type in 2022
- Based on End-User segmentation, Hospitals was the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Cancer Immunotherapy Market- Segmentation Analysis:
- The Global Cancer Immunotherapy Market is segmented on the basis of Product Type, Application, End-User, and Region.
- The market is divided into three categories based on product type: Monoclonal Antibodies, Cytokines & Immunomodulators, and Others. Monoclonal Antibodies dominate the market. Monoclonal antibodies (mAbs) are a type of cancer immunotherapy that has become an essential component in the treatment of various cancers. These are lab-created compounds that can imitate the immune system's ability to combat dangerous infections such as cancer cells.
- The market is divided into six categories based on application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others. Lung Cancer dominates the market and is likely to maintain its dominance during the forecast period. Immunotherapy has emerged as an important complement to lung cancer treatment options. Chemotherapy and radiation were the principal treatment choices for lung cancer for many years.
- The market is divided into three categories based on End-User: Hospitals, Cancer Research Centers, and Clinics. The hospital segment dominates the market growth. Cancer immunotherapy is widely employed in hospitals and clinics all over the world, from small hospitals to large university medical institutes.
Cancer Immunotherapy Market- Geographical Insights:
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the market, owing to an increase in healthcare expenditure, a rise in the incidence of cancer, and a surge in access to medical insurance. North America, especially the United States, spends more per capita on healthcare than any other country in the world. Because of this high level of spending, both the public and commercial sectors can invest in novel and frequently expensive cancer treatments, such as immunotherapies. According to American Medical Association, Health spending in the U.S. increased by 2.7% in 2021 to USD 4.3 trillion or USD12,914 per capita. The availability of health insurance can have a substantial impact on a patient's capacity to receive timely and high-quality care. Europe is the second largest region for the growth of the market, owing to the development in the infrastructure in the region and rising incidences of cancer.
Cancer Immunotherapy Market- Competitive Landscape:
The expanding worldwide burden of cancer and the established efficacy of immunotherapies in treating specific forms of cancer have increased the demand for cancer immunotherapy. Companies in this industry frequently compete on factors such as particular treatments' efficacy and safety profile, the spectrum of malignancies their medications can treat, pricing, and their ability to demonstrate the value of their therapies to consumers. They compete in terms of their R&D pipelines as well, as novel medicines and indications can provide a competitive advantage. This field has seen major innovation in recent years, leading to the development of new therapies and techniques. For example, on November 2022, Pfizer Inc. nowadays announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM).
Recent Developments:
On June 2023, Merck, known as MSD outside of the United States and Canada, nowadays announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck's anti-PD-1 therapy, in combination with standard of care chemotherapy for the treatment of patients with locally advanced unrespectable or metastatic biliary tract cancer (BTC).
Key features of the study:
- This proposed research study on Cancer Immunotherapy market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the Cancer Immunotherapy market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Cancer Immunotherapy market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Cancer Immunotherapy market
- Impact of COVID-19 on Cancer Immunotherapy market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Cancer Immunotherapy market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the Cancer Immunotherapy market, we have also included competitive landscape and key innovator analysis for the Cancer Immunotherapy market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Cancer Immunotherapy market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global Cancer Immunotherapy market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CANCER IMMUNOTHERAPY MARKET KEY PLAYERS
- Pfizer Inc.
- AstraZeneca
- Merck & Co., Inc
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Novartis AG
- Lilly
- Johnson & Johnson Services, Inc
- Immunocore, Ltd
GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE
- Monoclonal Antibodies
- Cytokines & Immunomodulators
- Others
GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Others
GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END-USER
- Hospitals
- Cancer Research Centers
- Clinics
GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA